|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> Pracinostat>> 市场分析报告 |
Pracinostat市场分析报告 |
|
MEI Pharma Inc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone ... and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase ... Acute Myeloid Leukaemia:KOL Insight ... /Venclyxto (venetoclax), Helsinn/MEI Pharma’s pracinostat and Roche’s idasanutlin and reveal ... ) Venclexta/Venclyxto (venetoclax; AbbVie/Roche) pracinostat (Helsinn/MEI Pharma) idasanutlin (Roche ... Global Essential Thrombocythemia Drug Market Report 2020 ... —— Product Type Segmentation Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Industry Segmentation Research ... Global Essential Thrombocythemia Drug Market Status, Trends and COVID-19 Impact Report 2022 ... —— Product Type Segment Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Application Segment Research ... Global Essential Thrombocythemia Drug Market Growth 2024-2030 ... value. Segmentation by type Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Others Segmentation by application ... Essential Thrombocythemia Drug Market, Global Outlook and Forecast 2022-2028 ... Percentages, by Type, 2021 (%) Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Others Global Essential ... Global Thrombocythaemia Myelofibrosis Treatment Market Growth (Status and Outlook) 2024-2030 ... historical data, market segmentation by Type (e.g., Pracinostat, Luminespib), and regional breakdowns. Market ... by Application in terms of value. Segmentation by type Pracinostat Luminespib Simtuzumab INCB-39110 Others ... Thrombocythaemia Myelofibrosis Treatment Market, Global Outlook and Forecast 2022-2028 ... China is Forecast to Reach $ Million by 2028. Pracinostat Segment to Reach $ Million by 2028, with ... Market Segment Percentages, by Type, 2021 (%) Pracinostat Luminespib Simtuzumab INCB-39110 Others ... Global Essential Thrombocythemia Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031 ... . Market segment by Type Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Others Market segment ... Global Thrombocythaemia Myelofibrosis Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028 ... at a % CAGR in next six years. While Pracinostat segment is altered to a % CAGR between 2022 ... markets. Market segment by Type, covers Pracinostat Luminespib Simtuzumab INCB-39110 Others ... Global Essential Thrombocythemia Drug Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries ... in this report are: Givinostat Idasanutlin Pracinostat Ruxolitinib Phosphate Others Most widely ... Acute Myeloid Leukemia (AML) Therapeutics: Market Research Report This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 ... Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017 This report can be delivered to the clients within 25 Hours DelveInsight’s, “Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017” report provides comprehensive insights of the ongoing therapeutic research and ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H2 2018 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 ... Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase ... Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H1 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Histone Deacetylase 2 - Pipeline Review, H1 2018'; Histone ... Histone Deacetylase 4 - Pipeline Review, H2 2020 Histone Deacetylase 4 - Pipeline Review, H2 2020 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine ... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drugs in Development, 2021 Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drugs in Development, 2021 SUMMARY Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 ... (COVID Version) Global Thrombocythaemia Myelofibrosis Treatment Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use ... . Novartis AG Pfizer Inc Market by Type Pracinostat Luminespib Simtuzumab INCB-39110 Others ... |